AU2001272490A1 - Use of galiella lactone - Google Patents

Use of galiella lactone

Info

Publication number
AU2001272490A1
AU2001272490A1 AU2001272490A AU7249001A AU2001272490A1 AU 2001272490 A1 AU2001272490 A1 AU 2001272490A1 AU 2001272490 A AU2001272490 A AU 2001272490A AU 7249001 A AU7249001 A AU 7249001A AU 2001272490 A1 AU2001272490 A1 AU 2001272490A1
Authority
AU
Australia
Prior art keywords
galiella lactone
galiella
lactone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001272490A
Inventor
Heidrun Anke
Timm Anke
Dr. Jorg Baumgarten
Gerhard Erkel
Marcus Weidler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ibwf Institut fur Biotechnologie und Wirkstoff-Forschung Ev
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000132242 external-priority patent/DE10032242A1/en
Priority claimed from DE2000147295 external-priority patent/DE10047295A1/en
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2001272490A1 publication Critical patent/AU2001272490A1/en
Assigned to ibwf Institut fur Biotechnologie und Wirkstoff-Forschung e.V. reassignment ibwf Institut fur Biotechnologie und Wirkstoff-Forschung e.V. Request for Assignment Assignors: BAYER AKTIENGESELLSCHAFT
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
AU2001272490A 2000-07-03 2001-06-20 Use of galiella lactone Abandoned AU2001272490A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10032242 2000-07-03
DE2000132242 DE10032242A1 (en) 2000-07-03 2000-07-03 Medicinal use of galiella lactone as specific interleukin-6 signal induction inhibitor e.g. in treatment of fibrotic, cerebrovascular or neurodegenerative disease, pain, inflammation or tumors
DE2000147295 DE10047295A1 (en) 2000-09-25 2000-09-25 Medicinal use of galiella lactone as specific interleukin-6 signal induction inhibitor e.g. in treatment of fibrotic, cerebrovascular or neurodegenerative disease, pain, inflammation or tumors
DE10047295 2000-09-25
PCT/EP2001/006935 WO2002002109A1 (en) 2000-07-03 2001-06-20 Use of galiella lactone

Publications (1)

Publication Number Publication Date
AU2001272490A1 true AU2001272490A1 (en) 2002-01-14

Family

ID=26006263

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001272490A Abandoned AU2001272490A1 (en) 2000-07-03 2001-06-20 Use of galiella lactone

Country Status (6)

Country Link
US (1) US6512007B1 (en)
EP (1) EP1408959A1 (en)
JP (1) JP2004501970A (en)
AU (1) AU2001272490A1 (en)
CA (1) CA2414660A1 (en)
WO (1) WO2002002109A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150531B2 (en) 2010-07-19 2015-10-06 Glactone Pharma Development Ab Tricyclic lactones for treatment of cancer
EP3114114B1 (en) 2014-03-07 2018-10-10 Glactone Pharma Development AB Tricyclic prodrugs
SE539204C2 (en) 2015-06-05 2017-05-09 Glactone Pharma Dev Ab Ether analogues of galiellalactone
SE540295C2 (en) 2016-12-05 2018-05-29 Glactone Pharma Dev Ab Sulfonamide analogues of galiellalactone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19801647A1 (en) * 1998-01-17 1999-07-22 Bayer Ag New beta, gamma-fused lactone glutamate receptor modulators for treating cerebral ischemia, cranial or brain trauma, pain or CNS-mediated spasms

Also Published As

Publication number Publication date
JP2004501970A (en) 2004-01-22
US6512007B1 (en) 2003-01-28
EP1408959A1 (en) 2004-04-21
WO2002002109A1 (en) 2002-01-10
CA2414660A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
AU2001291859A1 (en) Use of copolycarbonates
AU2002226486A1 (en) Novel c-glycoside derivatives and use thereof
AU2002226487A1 (en) Novel c-glycoside derivatives and use thereof
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2001294912A1 (en) Hydroxyesters of 7-desmethylrapamycin
AU2001230537A1 (en) Pyridoxazine derivatives
AU2002224808A1 (en) Use of thienopyrimidines
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001259702A1 (en) Tissue regrafting
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU2002231206A1 (en) Treatment of depression
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2002227925A1 (en) Human beta-defensin-3
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2002214883A1 (en) Isolation of taxanes
AU2001272490A1 (en) Use of galiella lactone
AU2001245950A1 (en) Preparation of deoxynucleosides
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AUPR069500A0 (en) Tissue modification

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application